Dr. Yang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4100 John R St
Detroit, MI 48201Phone+1 800-527-6266Fax+1 313-831-4065
Education & Training
Ascension Providence/MSUCHMFellowship, Hematology and Medical Oncology, 2008 - 2011- Ascension Providence/MSUCHMResidency, Internal Medicine, 2005 - 2008
- Ascension Providence/MSUCHMInternship, Transitional Year, 2004 - 2005
University of Michigan Medical SchoolClass of 1998
Certifications & Licensure
MI State Medical License 2004 - 2026- American Board of Internal Medicine Hematology
Clinical Trials
- Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation Start of enrollment: 2021 Nov 11
- A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies Start of enrollment: 2020 Aug 07
- A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2022 Dec 12
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsEnhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro.Katie H Hurrish, Yongwei Su, Shraddha Patel, Cassandra L Ramage, Jianlei Zhao
Biochemical Pharmacology. 2024-02-01 - 4 citationsAcquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms.Jenna L Carter, Yongwei Su, Xinan Qiao, Jianlei Zhao, Guan Wang
Biochemical Pharmacology. 2023-10-01 - 42 citationsOlutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.Stéphane de Botton, Pierre Fenaux, Karen Yee, Christian Récher, Andrew H Wei
Blood Advances. 2023-07-11
Abstracts/Posters
- Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with...Jay Yang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...Jay Yang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Na¥ve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive...Jay Yang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
What Is Leukemia? Symptoms, Causes and TreatmentJune 23rd, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
